ReviewNature reviews. Gastroenterology & hepatology2011
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
Review in Nature reviews. Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 117 citations in OpenAlex.
- Prognosis Relevance of Serum Cytokines in Pancreatic Cancer.BioMed research international · 2015Trial
- A Candidate Small Molecule Targeting Tachykinin Receptor 1 Suppresses Substance P‑Driven Extracellular Signal-Regulated Kinase Activation and Tumor Innervation in Pancreatic Cancer.ACS pharmacology & translational science · 2026Article
- PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma.Cancer letters · 2026Review
- Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer.Cells · 2026Article
- The Construction of ceRNA Regulatory Network Unraveled Prognostic Biomarkers and Repositioned Drug Candidates for the Management of Pancreatic Ductal Adenocarcinoma.Current issues in molecular biology · 2025Article
- An integrative multi-omics analysis reveals a multi-analyte signature of pancreatic ductal adenocarcinoma in serum.Journal of gastroenterology · 2025Article
- Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient-derived xenograft models.Molecular oncology · 2025Article
- SAMD1 suppresses epithelial-mesenchymal transition pathways in pancreatic ductal adenocarcinoma.PLoS biology · 2024Article
- mRNA vaccine development and applications: A special focus on tumors (Review).International journal of oncology · 2024Review
- Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction.Scientific reports · 2024Article
- An insight to PDAC tumor heterogeneity across pancreatic subregions using computed tomography images.Frontiers in oncology · 2024Article
- Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity.Biomicrofluidics · 2023Review
- DDX18 drives tumor immune escape through transcription-activated STAT1 expression in pancreatic cancer.Oncogene · 2023Article
- Differential expression and bioinformatics analysis of exosome circRNAs in pancreatic ductal adenocarcinoma.Translational oncology · 2023Article
- Integrated Bioinformatics Analysis Identifies Crucial Biochemical Processes Shared between Pancreatitis and Pancreatic Ductal Adenocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine.Military Medical Research · 2022Review
- Review
- Review
- Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.World journal of gastroenterology · 2022Review
- Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing.International journal of molecular sciences · 2022Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current standard therapies for pancreatic ductal adenocarcinoma have failed to attenuate the aggressiveness of this disease or confer notable improvements in survival. Previous molecular research into pancreatic cancers, along with advances in sequencing technologies, have identified many altered genes in patients with pancreatic cancer and revealed the marked genetic heterogeneity of individual tumors. Thus, the lack of success of conventional empiric therapy can be partly attributed to the underlying heterogeneity of pancreatic tumors. The genetic alterations that have been detected in pancreatic cancer range from simple mutations at the level of base pairs to complex chromosomal structural changes and rearrangements. The identification of molecular changes that are unique to an individual patient's tumors, and the subsequent development of strategies to target the tumors in a personalized approach to therapeutics, is a necessary advance to improve therapy for patients with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.